Greg Roumeliotis

Greg Roumeliotis is the Vice President of Global Business Development at Orgenesis. Greg has over 20 years of experience in the biotech industry, with a focus on genomics and machine learning.

Roumeliotis was previously the Vice President of Business Development at Breakthrough Genomics, where they helped found the company and develop its ENLITERTM platform. ENLITERTM is a machine learning platform that analyzes genomic data for clinical purposes. The platform is able to provide accurate diagnoses for patients in a fraction of the time and at a lower cost compared to the industry clinical standard.

Roumeliotis has a passion for using machine learning to improve healthcare and make it more accessible to everyone. Greg believes that the data produced by ENLITERTM will help physicians more accurately diagnose and treat each individual patient.

Greg Roumeliotis has a Master of Science in Health Care Policy & Management from the University of Birmingham and a BA in Economics from The American College of Greece.

Greg Roumeliotis reports to Vered Caplan, CEO. Greg Roumeliotis works with Heiko Von Der Leyen - Medical Director, Lilach Harel - VP of Global Human Resources, and Evan Fishman - Chief Financial Officer.